Skip to main content
Kindstar Globalgene Technology, Inc. logo

Kindstar Globalgene Technology, Inc. — Investor Relations & Filings

Ticker · 9960 ISIN · KYG5262E1044 HKEX Human health and social work activities
Open in API
Filings indexed 605 across all filing types
Latest filing 2021-09-15 Capital/Financing Update
Country HK Hong Kong
Listing HKEX 9960

About Kindstar Globalgene Technology, Inc.

http://www.kindstar.com.cn

Kindstar Globalgene Technology, Inc. is a leading independent provider of advanced specialty clinical testing services, specializing in esoteric testing. The company maintains the largest esoteric testing portfolio in its market, utilizing internationally-advanced laboratory facilities for clinical testing, scientific research, and applied R&D. Its comprehensive testing menu, featuring over 100 items, covers critical diagnostic areas including hematology, genetic diseases, gynecology, infectious diseases, neurology, and oncology. These services provide physicians and patients access to specialized diagnostics crucial for the diagnosis and treatment of major diseases.

Recent filings

Filing Released Lang Actions
DISCLOSEABLE TRANSACTION FORMATION OF PARTNERSHIP
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kindstar Globalgene Technology, Inc. regarding the formation of a partnership involving capital contributions and investment purposes. It details the terms of the partnership agreement, parties involved, capital contributions, management, and regulatory implications under the Hong Kong Listing Rules. The document is a formal disclosure of a transaction that meets the criteria of a discloseable transaction under Chapter 14 of the Listing Rules. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about a capital investment transaction. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and content confirm it is a full announcement, not a brief notice or report publication announcement.
2021-09-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2021
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities, specifically focusing on share capital, issued shares, share options, and confirmations related to securities issued by Kindstar Globalgene Technology, Inc. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content includes detailed tables of share capital and share movements, confirmations by an executive director, and explanations of terms related to securities. This type of document is a regulatory filing that reports on share capital and securities movements but does not constitute a full financial report, earnings release, or management discussion. It is not an announcement of a report but a formal regulatory submission. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory compliance documents that do not fit other specific categories.
2021-09-03 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2021
Interim / Quarterly Report Classification · 95% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2021' and contains detailed unaudited condensed consolidated financial results for the six months ended June 30, 2021. It includes key financial data, business review, R&D activities, and operational highlights. The presence of actual financial data and substantive analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document is about 15,000 characters long, which is substantial and not a mere announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-30 English
CONNECTED TRANSACTION - ACQUISITION OF 43% EQUITY INTEREST IN THE TARGET COMPANY
Capital/Financing Update Classification · 95% confidence The document is an announcement from Kindstar Globalgene Technology, Inc. regarding the acquisition of a 43% equity interest in a target company. It details the terms of the Equity Transfer Agreement, parties involved, consideration, payment terms, conditions precedent, and reasons for the acquisition. The document references the Listing Rules of the Hong Kong Stock Exchange and discusses connected transaction implications. It is a detailed announcement about a corporate transaction involving acquisition of equity interest, not a full financial report or earnings release. It does not contain financial statements or quarterly results but focuses on the acquisition transaction details. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as acquisitions.
2021-08-19 English
Date of Board Meeting
Regulatory Filings Classification · 95% confidence The document is an announcement from Kindstar Globalgene Technology, Inc. regarding the date of a Board Meeting to consider and approve the interim results for the six months ended June 30, 2021. It does not contain the interim financial report itself, but rather informs about the meeting where such results will be discussed. The document is short (1472 characters) and serves as a notice of an upcoming board meeting related to financial results, not the results or report itself. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and notices that do not fit other categories.
2021-08-12 English
STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF THE OVER-ALLOTMENT OPTION
Capital/Financing Update Classification · 95% confidence The document is an announcement related to the stabilization actions, end of stabilization period, and lapse of the over-allotment option following a global offering of shares by Kindstar Globalgene Technology, Inc. It discusses details about share overallocation, borrowing shares to cover over-allocations, and market purchases during the stabilization period. The document does not contain financial statements or detailed financial performance data, nor is it a report like an annual or interim report. It is a regulatory announcement about capital market activities related to the company's share offering and stabilization process. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is over 6000 characters and contains substantive information about financing activities, not just a brief notice or report publication announcement.
2021-08-06 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.